Skip to main content

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights

View Additional ASH 2018 Coverage

Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018
Wayne Kuznar
Read More
Leukemia, Oncology
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
Read More
FDA Approvals
AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma
Wayne Kuznar
Read More
Leukemia, Oncology
First-Line Enasidenib Achieves Complete Remission in Older Patients with Acute Myeloid Leukemia and IDH2 Mutation
Charles Bankhead
Read More
Leukemia, Oncology
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
Read More
Lymphoma
Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma
Phoebe Starr
Read More
Immunotherapy, Oncology
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
Read More
Immunotherapy, Oncology
Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma
Phoebe Starr
Read More
Immunotherapy, Oncology
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
Read More
Practice Management
High Incidence of Adverse Events Linked to Significant Economic Burden in Patients with Chronic Lymphocytic Leukemia
Chase Doyle
Read More
Page 2 of 3
Results 11 - 20 of 24